Expanded conditional approval allows drugs that are undergoing their final clinical trial assessment and are supported by ...

Longevity seekers are taking rapamycin in hopes of living longer. Here's what a health and longevity doctor has to say about the drug.

Biodexa Announces Allowance of U.S. Patent Covering Oral Rapamycin Nanoparticle Preparations (“eRapa”) and Use Biodexa plans ...

Rapamycin is a naturally occurring compound primarily used to prevent organ rejection in transplant patients. It’s also considered a promising anti-aging drug among longevity seekers.

A newly published study in Genes & Diseases highlights the crucial role of the mammalian target of rapamycin (mTOR) pathway in the progression of diabetic nephropathy (DN) and explores its potential ...

The Fast Track designation is supported by data from a phase 2 trial that evaluated eRapa in 30 adult patients with FAP.

Biodexa Pharmaceuticals (BDRX) announced that the U.S. Patent and Trademark Office allowed has U.S. patent application No. 17/391.495 titled ...

His research showed that by using rapamycin, which slows down mTOR activity, it is possible to reduce aging-related diseases and promote longer, healthier lives. Research supports many of Dr ...

Aubrey de Grey had a large mouse study of combinations of antiaging treatments. They did show that combination treatments did ...

CARDIFF, UK / ACCESS Newswire / February 12, 2025 /Biodexa Pharmaceuticals PLC. (NASDAQ:BDRX), a clinical-stage biopharmaceutical company developing a pipeline of innovative products for the treatment ...

today announced that the U.S. Patent and Trademark Office allowed has U.S. patent application No. 17/391.495 titled "Oral Rapamycin Nanoparticle Preparations and Use” which was exclusively licensed to ...